Novo Nordisk A/S
Bioassay for insulin formulations

Abstract:

The invention relates to a bioassay of insulin peptide in oral formulations and low affinity insulin peptides in liquid formulations, by for quantifying phosphorylated Akt, thereby avoiding the interference of excipients in potency determination.